Mozaffari Jovein, Miriam http://orcid.org/0009-0001-5304-8943
Ihorst, Gabriele http://orcid.org/0000-0002-8091-1589
Duque-Afonso, Jesús http://orcid.org/0000-0002-8287-5673
Wäsch, Ralph http://orcid.org/0000-0002-0813-3444
Bertz, Hartmut
Wehr, Claudia
Duyster, Justus
Zeiser, Robert http://orcid.org/0000-0001-6565-3393
Finke, Jürgen http://orcid.org/0000-0002-1799-5927
Scherer, Florian http://orcid.org/0000-0001-9635-5487
Article History
Received: 1 October 2023
Revised: 16 November 2023
Accepted: 20 November 2023
First Online: 10 December 2023
Competing interests
: MMJ declares no competing interests. FS receives research funding from Roche Sequencing Solutions, Gilead, and Takeda, and receives honoraria from AstraZeneca. JF declares no competing interests. GI declares no competing interests. JD-A received speakers honoraria from Roche, Amgen, Riemser, SOBI, IPSEN, NovoNordisk and AstraZeneca and travel support from Lilly, Roche, Gilead and SOBI. JD declares no competing interests. CW received honoraria from Takeda. HB declares no competing interests. RW received honoraria from Abbvie, Amgen, BMS/Celgene, Janssen, Kite/Gilead, Novartis, Pfizer and Sanofi. RZ received honoraria from Incyte, Novartis, Sanofi and Mallinckrodt all outside of the work reported here.